Clinical trial NCT02074449: Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)
Official title: Comprehensive Characterization Of Right Ventricular Performance And Afterload In Patients With Pulmonary Arterial Hypertension Undergoing Initiation And Rapid Dose Escalation Of Treprostinil
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Arterial Hypertension
Keywords: Pulmonary Arterial Hypertension
Right Ventricular Performance
Treprostinil
Remodulin
Lead sponsor: University of Arizona
Sponsor class: OTHER
Collaborators: name: United Therapeutics
First posted: 2014-02-28
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Pulmonary Arterial Hypertension

Brief summary: Patients with pulmonary arterial hypertension (PAH) are at much higher risk of death if the RV (right ventricle) is weak. The purpose of this study is to get a better understanding of the factors that determine RV adaptation and how the RV compensates on therapy. The investigator is also interested in how Remodulin (treprostinil) infused over a short period (approximately 48-72 hours) affects the patient's quality of life, medical care, and personal health behaviors.

Treprostinil, also known as Remodulin, has been approved by the US Food and Drug Administration for use in the treatment of PAH. The investigator has been treating patients with Remodulin by rapid infusion (over 48 hours) for over 6 years. The investigator would like to establish this practice as safe and effective for the benefit of other centers that treat PAH.


Eligibility criteria: Inclusion Criteria:

* Patients with clinically suspected World Health Organization (WHO) group I PAH
* Patients with New York Heart Association/WHO functional class II-IV
* Patients with mean pulmonary artery pressure \>25 mmHg, pulmonary capillary wedge pressure \</=15 mmHg, and pulmonary vascular resistance \>3 wood units
* Age \>18 and \<80
* No evidence of active ischemic heart disease

Exclusion Criteria:

* Left ventricular ejection fraction \<50%
* Patients with significant restrictive lung disease (FVC \<60% predicted) and/or significant obstructive lung disease (FEV1 \<55% predicted) within 1 year of enrollment if pulmonary function testing is available
* Patients with significant, investigator-determined parenchymal lung disease on chest x-ray or CT of the chest
* History of pulmonary embolism within the last three months or chronic pulmonary embolism
* Poorly interpretable grey scale echocardiographic images
* Contraindications to right heart catheterization
* Moderate-severe aortic and mitral valve abnormality
* Active or previous use of pulmonary vasoactive medication within the previous 12 weeks
* Renal failure with serum creatinine clearance \<30 ml/hr
* High-probability ventilation-perfusion scan

Primary outcomes:
measure: Measurement of change in RV coupling index on treprostinil between baseline, titration at 48-72 hours, and 3 months.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tucson
country: United States
facility: University of Arizona
state: Arizona
Study officials:
affiliation: University of Arizona
name: Franz Rischard, D.O.
role: PRINCIPAL_INVESTIGATOR
References: